Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$9.15 -6.9%	$7.81	$1.80 ▼ $20.63	$90.95M	-0.79	816,991 shs	107,309 shs
ELEV Elevation Oncology	$0.37	$0.37	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
IMUX Immunic	$0.91 -6.7%	$0.86	$0.56 ▼ $2.11	$96.53M	1.39	1.12 million shs	1.21 million shs
ORMP Oramed Pharmaceuticals	$2.06 -1.0%	$2.15	$1.82 ▼ $3.09	$85.29M	1.6	78,682 shs	70,840 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-2.87%	+3.47%	+32.66%	+11.96%	-46.17%
ELEV Elevation Oncology	0.00%	0.00%	-2.67%	+11.25%	-48.64%
IMUX Immunic	+8.55%	+15.25%	+1.50%	+0.50%	-25.87%
ORMP Oramed Pharmaceuticals	0.00%	-0.48%	-1.89%	-3.26%	-11.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVO CervoMed	2.373 of 5 stars	3.4	2.0	2.5	1.7	0.6
ELEV Elevation Oncology	1.3694 of 5 stars	3.0	0.0	0.6	1.7	0.6
IMUX Immunic	2.7405 of 5 stars	3.6	1.0	3.2	2.5	0.6
ORMP Oramed Pharmaceuticals	0.4438 of 5 stars	0.0	3.0	1.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVO CervoMed	2.78	Moderate Buy	$23.71	159.17% Upside
ELEV Elevation Oncology	2.00	Hold	$2.62	616.89% Upside
IMUX Immunic	3.29	Buy	$7.50	721.83% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELEV, IMUX, CRVO, and ORMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $31.00
8/12/2025	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
8/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $15.00
8/11/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/29/2025	CRVO CervoMed	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $27.00
7/25/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVO CervoMed	$9.74M	8.69	N/A	N/A	$3.61 per share	2.53
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.34 per share	N/A
ORMP Oramed Pharmaceuticals	$1.34M	63.03	N/A	N/A	$3.75 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVO CervoMed	-$16.29M	-$2.61	0.00	N/A	N/A	-290.72%	-59.15%	-53.64%	N/A
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	11/4/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	0.00	N/A	N/A	N/A	-461.46%	-217.16%	11/6/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.35	0.00	N/A	N/A	N/A	-19.37%	-18.28%	11/6/2025 (Estimated)

Latest ELEV, IMUX, CRVO, and ORMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ORMP Oramed Pharmaceuticals	-$0.04	-$0.05	-$0.01	$0.31	N/A	N/A
8/8/2025	Q2 2025	CRVO CervoMed	-$0.57	-$0.70	-$0.13	-$0.70	$1.45 million	$1.76 million
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVO CervoMed	N/A	8.20	8.20
ELEV Elevation Oncology	0.67	19.40	19.40
IMUX Immunic	N/A	2.19	2.19
ORMP Oramed Pharmaceuticals	N/A	26.82	23.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVO CervoMed	25.15%
ELEV Elevation Oncology	83.70%
IMUX Immunic	51.82%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
CRVO CervoMed	35.40%
ELEV Elevation Oncology	8.10%
IMUX Immunic	4.60%
ORMP Oramed Pharmaceuticals	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVO CervoMed	4	9.25 million	5.98 million	Not Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
IMUX Immunic	70	98.65 million	94.11 million	Optionable
ORMP Oramed Pharmaceuticals	10	41.00 million	33.58 million	Optionable

ELEV, IMUX, CRVO, and ORMP Headlines

Recent News About These Companies

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Misses Expectations By $0.01 EPS

August 18 at 3:52 PM | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?

August 15, 2025 | marketbeat.com

Oramed Pharmaceuticals (ORMP) to Release Earnings on Wednesday

August 7, 2025 | marketbeat.com

Zacks Small Cap Has Negative Outlook for ORMP Q2 Earnings

August 1, 2025 | marketbeat.com

With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio

July 29, 2025 | msn.com

BML Capital Management LLC Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

July 26, 2025 | marketbeat.com

ORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

ORMP - Oramed Pharmaceuticals Inc Executives - Morningstar

June 27, 2025 | morningstar.comM

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

June 27, 2025 | finance.yahoo.com

Oramed Pharm Extends Stock Buyback Program

May 21, 2025 | tipranks.com

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

May 17, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology

February 11, 2025 | contractpharma.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELEV, IMUX, CRVO, and ORMP Company Descriptions

CervoMed NASDAQ:CRVO

$9.15 -0.68 (-6.92%)

Closing price 04:00 PM Eastern

Extended Trading

$9.24 +0.09 (+0.98%)

As of 07:35 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Immunic NASDAQ:IMUX

$0.91 -0.07 (-6.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 +0.02 (+2.34%)

As of 07:56 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.06 -0.02 (-0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 +0.01 (+0.49%)

As of 04:10 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time